Leaky pipelines for Canadian women in research

Posted on behalf of Lesley Evans Ogden.

{credit}Council of Canadian Academies{/credit}

They call it a leaky pipeline. But the leaks are women, not oil. A substantial number of young women enter into potential research careers but drop-off at various stages, says a report released this week by the Canadian Council of Academies analyzing the gender gap amongst Canada’s University researchers.

There are more than twice as many male than female researchers at Canadian research institutions, despite the fact that undergraduate enrollment achieved gender parity in 1989, and more than 50% of Canadian PhD students are now female.

The CCA panel sought to explain this attrition of women at ascending rungs of the faculty ladder. Low female numbers in the Canada Research Chairs (CRC) programme, and their absence from the Canada Excellence Research Chairs (CERC) program, were key drivers in the commissioning of the report.

One challenge was the paucity of data for tracking career trajectories. Data is scarce at the postdoctoral stage and beyond, making this phase a particular mystery.

But there are clues.

Despite progress in institutional policies allowing career interruptions for child rearing, “there are still important difficulties that women researchers face more than men with respect to having a family”, says the University of Ottawa’s Michael Wolfson, a report co-author. The traditional pressures of institutional culture may trump policy in an increasingly competitive funding environment, explains Janet Halliwell, President of J.E. Halliwell Associates, one of the report’s external reviewers.

Male faculty father children in their late 20s and early 30s, while women faculty have fewer children, and postpone childbearing to later ages, “which we took to be a signal of the more difficult choice or trade-off that women faced with respect to balancing a research career,” says Wolfson. Some call it the “maternal wall”.

“The relatively low proportion of women at the full professor level suggests that the glass ceiling remains intact in Canada as well as in several comparator countries,” says the report.

Are things improving? Yes. The gap is closing, but not fast enough. If we take a wait and watch approach, parity is still decades away, explains Wolfson.

What can be done? The report makes many suggestions. We need better data on research career trajectories from granting councils and academic institutions. Second, we need a more family-friendly academic environment that is flexible with respect to part time work and interrupted careers.

With leaky pipelines, maternal walls, and glass ceilings to fix, the report is a call to action at all levels. Canada needs to “engineer” more women into research, and find mechanisms to collect the very data we need to both monitor and make it happen.

Read Nature‘s editorial on what we are doing to try and improve our coverage of the contributions of women to science.

Dutch nanoscientists get €51 million to push limits

Posted on behalf of Sonja van Renssen.

A new €51-million (US$65 million) nanoscience programme in the Netherlands is setting out to identify and redraw the boundaries of nanotechnology. The ‘NanoFront’ project has won the lion’s share — €36 million — of a new €167-million pot of fundamental science-research funding in the Netherlands, one of the country’s largest ever. The two universities behind the project, Delft University of Technology (TU Delft) and the University of Leiden, are topping this up with €15 million of their own.

The goal of the new 10-year programme is threefold: to investigate the limits of the quantum world of materials, to understand the tiniest building blocks of living cells and to develop new technologies to be able to videos the nano world in real time.

“We will be observing, monitoring and developing material at the ultimate scale: atom for atom, in a way that was completely inconceivable a few years ago,” says research leader Cees Dekker, director of the Delft Kavli Institute at TU Delft. This institute recently discovered the Majorana fermion particle, which could help deliver future quantum computers.

NanoFront’s goal is to move beyond pure science to real physical applications. It will seek to answer questions such as: how big can a quantum object get before it stops obeying the laws of quantum mechanics? One of the goals is to explore building computer circuits out of molecules, which would enable much faster processing than exists today.

On the bio-nanoscience side, the aim is to understand how biology works at the quantum level: how do living and dead matter interact at the atomic scale? The researchers in Delft and Leiden want to study life’s tiniest components, try making their own and finally come up with a tool kit for building a basic cell. Personalized medicine would be one beneficiary.

‘The goal is to both explore and exploit nanoscience,” sums up Dekker. He expects NanoFront to create around 100 new positions, including seven for prominent international scientists.

Psychologists do some soul-searching

Posted on behalf of Ed Yong.

Psychologists are going through a period of intense self-reflection regarding the reliability of research in their field, fuelled by recently uncovered cases of fraud, failed attempts to replicate classic results, and calls from prominent psychologists to replicate key results in disputed fields.

The latest volley in this debate is a special issue of Perspectives on Psychological Science, consisting of 18 papers that outline the scope of the so-called “replicability crisis”, and potential ways of fixing it.

Among the contributions, Matthew Makel from Duke University and two other colleagues have uncovered just how uncommon replications are in psychology, especially from independent groups. By scanning the top 100 psychology journals since 1900, and analysing 500 randomly selected articles more deeply, they showed that just 1% of publications are replications of earlier work. Of these, only 14% are direct replications that follow the original experimental recipes, while the others are conceptual replications that test related hypotheses using different methods and settings.

Makel also found that around half of these replications are done by the same scientists behind the original experiments (and many are published as part of the original papers). This matters because the odds that the replication will be successful are 92% if the original authors were involved, but just 65% if done by an independent group.

This lack of independent replications, combined with the low statistical power of many studies and the tendency to only publish positive results, is a serious problem, according John Ioannidis from Stanford School of Medicine in California. In a commentary, Ioannidis, probably the biggest name in the meta-field of scientific credibility, writes that “the overall credibility of psychological science at the moment may be in serious trouble”.

Later papers in the issue outline potential ways of fixing these problems by encouraging more replications, including: using undergraduate projects as a route for replicating existing studies; encouraging adversarial collaborations where sceptics replicate studies alongside original investigators;  providing accessible outlets for publishing replications; opening up data, methods and workflow; and pre-registering studies including all the intended methods and analyses.

Many of these reforms should be enacted in parallel, argue the issue’s editors, Hal Pashler from University of California, San Diego and Eric-Jan Wagenmakers from University of Amsterdam. They write that psychologists have “found ourselves in the very unwelcome position of being… the public face for the replicability problems of science in the early 21st century”. But they also see a solid opportunity “to rise to the occasion and provide leadership in finding better ways to overcome bias and error in science generally”.

Ruth’s Reviews – My Beautiful Genome

Ruth Francis, Nature’s head of press, is reading the shortlist of the Royal Society Winton prize for science books at a rate of one a week. She’s done it before. Will she succeed this year? The winner of the prize will be announced on 26 November.

Frank by name and frank by nature; My Beautiful Genome begins with the quirky and honest unveiling of a forceful personality and a family history of depression.

But for all of its exploration of the author’s own traits, this could just as aptly be named ‘Our Beautiful Genomes’. Personal genomics has a long way to go before it achieves its promise and becomes particularly insightful to any individual. As Lone Frank discovers on her adventures through her own genetic make up, it is not yet beneficial to look at individual dimensions. We may assess a population, or get an overview of a person, but can we learn anything specific that we did not already know through experience?

Frank derives a sense of satisfaction at finding a genetic basis for her lack of agreeableness, or propensity to irritation with others. But of course, she was already aware of her foibles and stated them outright in the opening pages. Tests for specific gene variants of BDNF which can affect how women handle stress – and SERT – which is linked with depression – again validate something she already knew.

It is clear that genomics is a fast moving and rapidly expanding field. Like its subject matter, the book quickly becomes technical, covering a lot of ground in the early chapters, presumably in order to bring the reader up to speed.

The fact that many studies flagged as embryonic in these early passages have now been published, such as the 1,000 genomes study from the 1000 Genomes Project, that appeared this very week in Nature, is testament to the pace of research. But even as a relatively well-versed reader, I found the level of detail hard-going.

The writing style is direct and confident. The reader is treated with an intellectual respect that is both flattering and educational. One weakness though, is in the interviews. Frank paints vivid pictures of her subjects, and their surroundings. She seems insightful and reads them well, but reproduces interviews almost verbatim, which I found frustrating given her talents in summarising complex information elsewhere. Perhaps this is a direct result of her personality test scores: high in openness and empathy, but low on agreeableness and compliance. Nevertheless this is a captivating, instructional, and enjoyable read.

MS treatment shows success in clinical trials

Posted on behalf of Duncan Graham-Rowe.

It is what multiple sclerosis sufferers have long hoped for, a drug that can not only halt the progression of nerve damage caused by the disease but also reverse it (see ‘Antibody offers hope for multiple sclerosis treatment‘). Yet as the monoclonal antibody alemtuzumab clears its last hurdle before clinical approval it now seems clear it will come at a price.

According to the results of the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I and II, two phase III clinical trials published in The Lancet today, 78% and 65% of patients on alemtuzumab, respectively, remained free of relapse after two years, compared with 47% on a standard therapy, interferon beta-1a (marketed as Rebif). CARE-MS II also found that on average patients taking alemtuzumab had less disability at the end of the study than when they started, while those on interferon beta-1a experienced a worsening.

Further evidence of a reversal comes in the form of MRI scans of patients brains, says Alasdair Coles, lead author of the papers and a clinician at the University of Cambridge. In both trials patients on alemtuzumab showed significantly less brain volume loss, a proxy measure for tissue damage caused by MS. “In fact, the rate of brain atrophy after alemtuzumab approached the rate you would see in a healthy person,” he says.

But MS sufferers’ gain could prove to be a loss for leukemia patients. Alemtuzumab is already on the market for treating B-cell chronic lymphocytic leukemia. Yet in August Genzyme, the Cambridge, Massachusetts-based, company that makes the drug, voluntarily withdrew Alemtuzumab from the market. Genzyme cites commercial reasons, but with the recent trend of clinicians using the drug off-label to treat their MS patients ahead of clinical approval, its withdrawal seems a telltale sign of an impending price hike.

Even so this is good news for MS patients. There is no cure for the disease, which occurs when the body’s own immune system attacks the myelin sheath that normally protects the nerves and speeds up neurological signals in the brain and spinal cord, and so far alemtuzumab is the only drug to show signs of reversing this damage. What’s more it can do so after just two intravenous infusions given a year apart.

“These trial results show that alemtuzumab is a robust and effective treatment for multiple sclerosis, both in people with multiple sclerosis which has never been treated, and those whose disease has already ‘broken through’ standard treatment,” says Coles. With clinical approval expected both in Europe and the US as early as next summer, research will continue to evaluate its long-term efficacy.

 

Ruth’s Reviews – Moonwalking with Einstein

Ruth Francis, Nature’s head of press, is reading the shortlist of the Royal Society Winton prize for science books at a rate of one a week. She’s done it before. Will she succeed this year? The winner of the prize will be announced on 26 November.

Humans, it seems, have always fretted about memory. Socrates worried that writing would be detrimental to memory. In the fifteenth century the Gutenberg press meant more access to books and less need to remember for ourselves. Today fact-checking via the internet is at our fingertips around the clock.

Joshua Foer’s Moonwalking with Einstein is an exploration of memory in which we meet extreme examples — people with extraordinary abilities to remember, and others who can only forget. Ultimately, however, it is the story of one man’s journey from average forgetfulness to competitor in the USA Memory Championship.

“What had begun as an exercise in participatory journalism had become an obsession,” writes Foer. “I had set out simply to learn what the strange world of the memory circuit was all about and find out if memory was indeed improvable.”

And it makes for participatory reading. I could not help but test some of the techniques he encountered during his year of obsession. At a recent party I was better able to remember names thanks to just one of the suggestions — to associate a new name with someone you already know with the same name.

Foer starts out as a reporter, writing about mental athletes, but he is quickly sucked into their sphere. He is taken under the wing of a British competitor, Ed, and becomes submersed in his world, with the ultimate aim of winning the USA Memory Championship the next year. En route he meets famous case studies and the scientists who worked with them, and becomes a case study in memory research in his own right.

In some ways I found the tales of famous savants, synaesthetes and memory miracles more immersive than Foer’s own journey. This isn’t to say that his own exploration is not engaging, but these one-offs are fascinating, and each gives us insight into how our own memories are processed.

These self-proclaimed Knights of Learning live in a strange world, almost entirely devoid of women, and I was glad someone else did the legwork so I could stand on the sidelines and cheer — without having to participate myself.

Italian court says mobile phones cause cancer

Posted on behalf of Nicola Nosengo.

In ruling on a workplace compensation case, Italy’s highest civil court has stated that mobile phones can cause brain tumours. The ruling is being criticized by medical experts in Italy and abroad, who note that no scientific study has yet proven a clear causal link between the use of mobile phones and health risks. In a 12 October decision that was made public this week, the Labour Law section of Italy’s High Court ruled in favour of Innocente Marcolini, a former commerce manager in Brescia. Marcolini had developed a tumour of the trigeminal ganglion, near his left ear, and claimed it was a consequence of speaking on a mobile phone up to 6 hours a day for 12 years because his job demanded it.  Although the tumour was successfully removed, Marcolini was left with severe problems (such as intense pain) and thus asked for compensation from INAIL, the Italian agency that insures work-related health risks. INAIL rejected his request, noting that there is not enough evidence linking mobile-phone use to brain tumours. In particular, it quoted conclusions from the World Health Organization (WHO), which in its literature states that “to date, no adverse health effects have been established as being caused by mobile phone use” (see ‘Mobile phones officially under suspicion’).

At first a civil court ruled against Marcolini, who appealed. The Appeal Court placed more weight on research done by Lennart Hardell’s group at the University of Örebro in Sweden, which years ago suggested that the use of mobile phones for more than ten years leads to increased risk for acoustic neuroma and glioma. The Appeal Court considered this work more “reliable” and more “independent” than large international studies such as the Interphone study (conducted by the International Agency for Research on Cancer and funded jointly by the industry and the European Commission), as Hardell’s studies were not funded by mobile-phone manufacturers. The Interphone study, published in 2010, failed to provide solid evidence that mobile phones increased the risk of brain tumours, although it hinted at a slightly higher risk for ‘heavy’ users (see ‘No link found between mobile phones and cancer’).

A further appeal from INAIL brought the case in front of the High Court, which has confirmed the Appeal Court’s decision and ruled once again in favour of Marcolini. The sentence is now final. Italian consumer advocacy organizations, such as CODACONS, celebrated the ruling, which they say will create a precedent that allows consumers who use mobile phones for many hours a day to sue mobile-phone manufacturers if they develop a tumour.

But Michael Repacholi, former coordinator of the WHO’s Electromagnetic Fields Project, disagrees with the ruling and its motivations. “Funds [for the Interphone study] were provided to a committee of the International Union Against Cancer who acted as a firewall between the funders and sponsors so that the researchers had no contact with any of the sponsors,” he wrote in an e-mail to Nature. “Thus the industry contribution had absolutely no influence on the study outcome. It is unfortunate that the judge thought the Hardell study was the only independent one, when the WHO/IARC study was independent and was the largest study ever conducted on this topic”. Hardell could not be reached for comment.

Science panel urges halt to GM field trials in India

Posted on behalf of  K. S. Jayaraman.

The prospects for growing genetically modified (GM) food crops in India have receded further with the release of yet another damning report on 17 October.

A 5-member Technical Expert Committee (TEC) of scientists with expertise in agricultural biotechnology wants all open field trials stopped until better mechanisms for monitoring the trials and evaluating biosafety data are in place, and conflicts of interest in the regulatory body have been dealt with.

The panel was appointed by India’s Supreme Court in May in response to a petition from anti-GM activists. Its report echoes the conclusions of a parliamentary panel in August, which also called for a moratorium on field trials (see ‘Indian parliamentary panel slams GM crops’).

The TEC goes further, however, calling for a re-examination of biosafety data on all GM crops already approved for field trials, and recommending long-term and inter-generational feeding studies in rodents for all products, whether already approved or yet to be approved. It also wants to prohibit field trials of GM versions of crops for which India is a centre of origin or a centre of diversity and wants trials of herbicide-tolerant crops banned “until independent assessment of their impact and suitability in the Indian context”.

The panel also proposes a 10-year moratorium on GM food crops that use the Bt (Bacillus thuringiensis) gene — a period it considers reasonable to strengthen the regulatory regime which it found unsatisfactory in its present form “with a lack of full time personnel and limited expertise in biosafety science”. The approval and subsequent cancellation of a plan to commercialise Bt Brinjal (eggplant) caused an uproar in India in 2009 and 2010 (see ‘India’s transgenic aubergine in a stew’).

“It is worth noting that the TEC consists only of scientists,” says Kavitha Kuruganti of the Coalition for GM free India. “Further, 22 of the 31 submissions studied by the TEC in their nearly 4-month-long inquiry were from people with a scientific background” from both private and public sector institutions.

But pro-GM scientists say they are shocked. “The TEC’s recommendations fly in the face of what we know in science,” says Sivramiah Shantharam, a professor at Iowa State University’s Seed Science Centre. “The only option left is for the farmers of India — who have benefited from Bt cotton — to get down to the street and demand the technology. No government or political party can ignore cries of farmers.”

The Supreme Court will now make a decision on the basis of this report and other evidence. A ruling could come as soon as the end of this month.

Vostok’s microbes elusive in first measurements of surface water

Posted on behalf of Naomi Lubick.

A first analysis of the ice that froze onto the drillbit used in last February’s landmark drilling to a pristine Antarctic lake shows no native microbes came up with the lake water, according to Sergey Bulat of Petersburg Nuclear Physics Institute (Russia). The very uppermost layer of Lake Vostok appears to be “lifeless” so far, says Bulat, but that doesn’t mean the rest of it is.

Bulat reported what he calls his team’s “very preliminary results” on Tuesday, at the 12th European Workshop on Astrobiology (ENEA 2012), in Stockholm, Sweden, at the AlbaNova University Center.

Bulat and his colleagues counted the microbes present in the ice sample and checked their genetic makeup to figure out the phylotypes. They counted fewer than 10 microbes/ml — about the same magnitude they would expect to find in the background in their clean room. And three of the four phylotypes they identified matched contaminants from the drilling oil, with the fourth unknown but also most likely from the lubricant.

Bulat hopes to get clean samples from the ice frozen in the borehole below where the drill bit stopped. That won’t be until next May (2013), if all goes well after the next Russian drilling expedition in December-January. Even if the top of the lake ends up being empty, Bulat suspects microbes will come from lower water depths, or from sediment samples at the bottom of the lake.

Lake Vostok is a stand-in for icy bodies that might harbor life, like Jupiter’s moon Europa. Gerda Horneck of the German Aerospace Center (DLR) said that any result from Lake Vostok is important for astrobiology, and the search for extremophiles that could give hints of what life could be like elsewhere. “Let’s see what comes out next round,” she told me at the end of the meeting on Wednesday.

Singing mice may join humans and songbirds as vocal learners

Cross posted from Scientific American’s The Thoughtful Animal blog on behalf of Jason Goldman.

{credit}Wikimedia Commons/George Shuklin.{/credit}

My high school biology teacher once told me that nothing was binary in biology except for alive and dead, and pregnant and not pregnant. Any other variation, he said, existed along a continuum. Whether or not the claim is technically accurate, it serves to illustrate an important feature of biological life. That is, very little in the biological world falls neatly into categories. A new finding, published today in PLoS ONE by Gustavo Arriaga, Eric P. Zhou, and Erich D. Jarvis from Duke University adds to the list of phenomena that scientists once thought were categorical but may, in fact, not be.

The consensus among researchers was that, in general, animals divide neatly into two categories: singers and non-singers. The singers include songbirds, parrots, hummingbirds, humans, dolphins, whales, bats, elephants, sea lions and seals. What these species all have in common – and what distinguishes them from the non-singers of the animal world – is that they are vocal learners. That is, these species can change the composition of their sounds that emanate from the larynx (for mammals) or syrinx (for birds), both in terms of the acoustic qualities such as pitch, and in terms of syntax (the particular ordering of the parts of the song). It is perhaps not surprising that songbirds and parrots have been extremely useful as models for understanding human speech and language acquisition. When other animals, such as monkeys or non-human apes, produce vocalizations, they are always innate, usually reflexive, and never learned.

But is the vocal learner/non-learner dichotomy truly reflective of biological reality? Maybe not. It turns out that mice make things more complicated.

Only in the last hundred years or so have researchers known that mice vocalize as part of their mating process. The reason it eluded scientists for so long is that their vocalizations can’t be heard by human ears. But then, in 2005, Holy and Guo argued in a paper in PLoS Biology that the ultrasonic vocalizations produced by mice ought to be thought of as songs rather than calls. Continue reading